Does the media refer more to ACRV or RNAC?

In the previous week, Acrivon Therapeutics and Acrivon Therapeutics both had 1 articles in the media. Acrivon Therapeutics' average media sentiment score of 0.00 equaled Cartesian Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cartesian Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ZNTL or ACRV more profitable?

Zentalis Pharmaceuticals' return on equity of -53.61% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -53.61% -40.67% Acrivon Therapeutics N/A -64.43% -57.08%

Does the media favor ZNTL or ACRV?

In the previous week, Zentalis Pharmaceuticals and Zentalis Pharmaceuticals both had 1 articles in the media. Zentalis Pharmaceuticals' average media sentiment score of 0.76 beat Acrivon Therapeutics' score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acrivon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, ACRV or NMRA?

Neumora Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A Neumora Therapeutics N/A N/A -$236.93M -$1.33 N/A

Is ACRV or NMRA more profitable?

Acrivon Therapeutics' return on equity of -64.43% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -64.43% -57.08% Neumora Therapeutics N/A -181.70% -119.15%

Does the media refer more to ACRV or NMRA?

In the previous week, Neumora Therapeutics had 12 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 13 mentions for Neumora Therapeutics and 1 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.00 beat Neumora Therapeutics' score of -0.67 indicating that Acrivon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neumora Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Negative

Does the media prefer ACRV or TRDA?

In the previous week, Entrada Therapeutics had 1 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 2 mentions for Entrada Therapeutics and 1 mentions for Acrivon Therapeutics. Entrada Therapeutics' average media sentiment score of 0.80 beat Acrivon Therapeutics' score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Entrada Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Acrivon Therapeutics (ACRV) Competitors

$1.57 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$1.56 -0.01 (-0.64%)

As of 05:06 AM Eastern

Compare

ACRV vs. RNAC, ZNTL, NMRA, TRDA, and AKBA

Should you buy Acrivon Therapeutics stock or one of its competitors? MarketBeat compares Acrivon Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acrivon Therapeutics include Cartesian Therapeutics (RNAC), Zentalis Pharmaceuticals (ZNTL), Neumora Therapeutics (NMRA), Entrada Therapeutics (TRDA), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry.

How does Acrivon Therapeutics compare to Cartesian Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Acrivon Therapeutics currently has a consensus price target of $11.67, suggesting a potential upside of 643.10%. Cartesian Therapeutics has a consensus price target of $32.60, suggesting a potential upside of 238.53%. Given Acrivon Therapeutics' higher probable upside, equities research analysts clearly believe Acrivon Therapeutics is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Acrivon Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

Acrivon Therapeutics has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

In the previous week, Acrivon Therapeutics and Acrivon Therapeutics both had 1 articles in the media. Acrivon Therapeutics' average media sentiment score of 0.00 equaled Cartesian Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cartesian Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Acrivon Therapeutics has higher earnings, but lower revenue than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Cartesian Therapeutics	$2.80M	101.05	-$130.30M	-$5.90	N/A

Summary

Cartesian Therapeutics beats Acrivon Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Zentalis Pharmaceuticals has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

71.6% of Acrivon Therapeutics shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by company insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Acrivon Therapeutics has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	3.91	-$137.06M	-$1.73	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A

Zentalis Pharmaceuticals' return on equity of -53.61% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
Acrivon Therapeutics	N/A	-64.43%	-57.08%

Zentalis Pharmaceuticals presently has a consensus price target of $5.83, suggesting a potential upside of 57.66%. Acrivon Therapeutics has a consensus price target of $11.67, suggesting a potential upside of 643.10%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Zentalis Pharmaceuticals and Zentalis Pharmaceuticals both had 1 articles in the media. Zentalis Pharmaceuticals' average media sentiment score of 0.76 beat Acrivon Therapeutics' score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acrivon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Acrivon Therapeutics beats Zentalis Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Neumora Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Acrivon Therapeutics' return on equity of -64.43% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Neumora Therapeutics	N/A	-181.70%	-119.15%

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Neumora Therapeutics had 12 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 13 mentions for Neumora Therapeutics and 1 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.00 beat Neumora Therapeutics' score of -0.67 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neumora Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Negative

Acrivon Therapeutics has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.74, indicating that its share price is 174% more volatile than the broader market.

Acrivon Therapeutics presently has a consensus target price of $11.67, indicating a potential upside of 643.10%. Neumora Therapeutics has a consensus target price of $6.86, indicating a potential upside of 354.12%. Given Acrivon Therapeutics' higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Neumora Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Neumora Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A

Summary

Acrivon Therapeutics beats Neumora Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Entrada Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Acrivon Therapeutics currently has a consensus target price of $11.67, suggesting a potential upside of 643.10%. Entrada Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 146.83%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Acrivon Therapeutics is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Acrivon Therapeutics has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

Acrivon Therapeutics has higher earnings, but lower revenue than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Entrada Therapeutics	$25.42M	10.83	-$143.75M	-$3.99	N/A

Acrivon Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

In the previous week, Entrada Therapeutics had 1 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 2 mentions for Entrada Therapeutics and 1 mentions for Acrivon Therapeutics. Entrada Therapeutics' average media sentiment score of 0.80 beat Acrivon Therapeutics' score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entrada Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Acrivon Therapeutics beats Entrada Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Akebia Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Akebia Therapeutics has higher revenue and earnings than Acrivon Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Akebia Therapeutics	$236.20M	1.22	-$5.34M	-$0.08	N/A

In the previous week, Acrivon Therapeutics had 1 more articles in the media than Akebia Therapeutics. MarketBeat recorded 1 mentions for Acrivon Therapeutics and 0 mentions for Akebia Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.00 equaled Akebia Therapeutics'average media sentiment score.

Company	Overall Sentiment
Acrivon Therapeutics	Neutral
Akebia Therapeutics	Neutral

Acrivon Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Akebia Therapeutics' return on equity of -62.72% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 10.5% of Acrivon Therapeutics shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Acrivon Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Acrivon Therapeutics presently has a consensus target price of $11.67, suggesting a potential upside of 643.10%. Akebia Therapeutics has a consensus target price of $4.67, suggesting a potential upside of 336.14%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Acrivon Therapeutics is more favorable than Akebia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Acrivon Therapeutics beats Akebia Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Acrivon Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACRV vs. The Competition

Export

Metric	Acrivon Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$67.20M	$2.96B	$6.41B	$12.59B
Dividend Yield	N/A	1.78%	2.68%	5.81%
P/E Ratio	-0.79	18.67	24.61	24.44
Price / Sales	N/A	312.96	529.91	111.09
Price / Cash	N/A	55.91	27.92	37.84
Price / Book	0.44	4.03	10.77	6.60
Net Income	-$77.90M	$64.45M	$3.57B	$337.10M
7 Day Performance	3.29%	0.10%	0.35%	-0.20%
1 Month Performance	-10.29%	-0.13%	-0.08%	1.68%
1 Year Performance	33.05%	26.02%	29.31%	36.09%

Acrivon Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACRV Acrivon Therapeutics	1.8871 of 5 stars	$1.57 flat	$11.67 +643.1%	+33.1%	$67.20M	N/A	N/A	58	High Trading Volume
RNAC Cartesian Therapeutics	2.2367 of 5 stars	$8.90 +3.5%	$32.60 +266.3%	-1.3%	$260.89M	$2.80M	N/A	64	Gap Up
ZNTL Zentalis Pharmaceuticals	2.2524 of 5 stars	$3.60 -4.8%	$5.83 +62.2%	+184.6%	$255.93M	$67.43M	N/A	160	Positive News
NMRA Neumora Therapeutics	3.0024 of 5 stars	$1.38 +50.4%	$7.14 +419.5%	+92.2%	$254.76M	N/A	N/A	108	Gap Up High Trading Volume
TRDA Entrada Therapeutics	3.843 of 5 stars	$6.52 -0.7%	$17.50 +168.4%	-0.4%	$253.30M	$25.42M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACRV) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acrivon Therapeutics (ACRV) Competitors

ACRV vs. RNAC, ZNTL, NMRA, TRDA, and AKBA

How does Acrivon Therapeutics compare to Cartesian Therapeutics?

Summary

How does Acrivon Therapeutics compare to Zentalis Pharmaceuticals?

Summary

How does Acrivon Therapeutics compare to Neumora Therapeutics?

Summary

How does Acrivon Therapeutics compare to Entrada Therapeutics?

Summary

How does Acrivon Therapeutics compare to Akebia Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV vs. The Competition

Acrivon Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acrivon Therapeutics (ACRV) Competitors

ACRV vs. RNAC, ZNTL, NMRA, TRDA, and AKBA

How does Acrivon Therapeutics compare to Cartesian Therapeutics?

Do analysts recommend ACRV or RNAC?

Is ACRV or RNAC more profitable?

Which has more risk & volatility, ACRV or RNAC?

Does the media refer more to ACRV or RNAC?

Do institutionals & insiders hold more shares of ACRV or RNAC?

Which has stronger earnings & valuation, ACRV or RNAC?

Summary

How does Acrivon Therapeutics compare to Zentalis Pharmaceuticals?

Which has more volatility and risk, ZNTL or ACRV?

Do insiders and institutionals hold more shares of ZNTL or ACRV?

Which has better valuation & earnings, ZNTL or ACRV?

Is ZNTL or ACRV more profitable?

Do analysts prefer ZNTL or ACRV?

Does the media favor ZNTL or ACRV?

Summary

How does Acrivon Therapeutics compare to Neumora Therapeutics?

Is ACRV or NMRA more profitable?

Do insiders and institutionals believe in ACRV or NMRA?

Does the media refer more to ACRV or NMRA?

Which has more risk and volatility, ACRV or NMRA?

Do analysts prefer ACRV or NMRA?

Which has stronger earnings and valuation, ACRV or NMRA?

Summary

How does Acrivon Therapeutics compare to Entrada Therapeutics?

Do analysts recommend ACRV or TRDA?

Which has more risk and volatility, ACRV or TRDA?

Which has higher earnings & valuation, ACRV or TRDA?

Is ACRV or TRDA more profitable?

Does the media prefer ACRV or TRDA?

Do insiders & institutionals hold more shares of ACRV or TRDA?

Summary

How does Acrivon Therapeutics compare to Akebia Therapeutics?

Which has preferable earnings and valuation, ACRV or AKBA?

Does the media refer more to ACRV or AKBA?

Is ACRV or AKBA more profitable?

Do insiders & institutionals hold more shares of ACRV or AKBA?

Which has more volatility & risk, ACRV or AKBA?

Do analysts recommend ACRV or AKBA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV vs. The Competition

Acrivon Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools